Antine Stenbit, MD
Pulmonary Disease · Hendersonville, NCNPI 1659475432
Payments from drug & device makers
Across 161 payments — averaging $199.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim Pharma GmbH & Co.kg$25K
- Sanofi$4K
- AstraZeneca$560
- Regeneron Healthcare Solutions, Inc.$449
- Actelion Pharmaceuticals US, Inc.$338
- GSK$216
- plus $2K from 27 others
What the payments were for
- Consulting fees$3,02042%
- Travel & lodging$581%
- Food & beverage$4,10957%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim Pharma GmbH & Co.kg | 2 | $24,760 |
| Sanofi | 10 | $3,577 |
| AstraZeneca | 24 | $560 |
| Regeneron Healthcare Solutions, Inc. | 17 | $449 |
| Actelion Pharmaceuticals US, Inc. | 11 | $338 |
| GSK | 13 | $216 |
| Boehringer Ingelheim | 5 | $179 |
| United Therapeutics Corporation | 8 | $169 |
| Phathom Pharmaceuticals, Inc. | 4 | $166 |
| Gilead | 3 | $147 |
| Abiomed | 1 | $146 |
| Amgen | 5 | $142 |
| Verona Pharma, Inc. | 10 | $137 |
| Baxter Healthcare | 5 | $135 |
| Sunovion Pharmaceuticals Inc. | 8 | $130 |
| Grifols USA, LLC | 6 | $127 |
| Advanced Respiratory, Inc | 4 | $127 |
| Insmed, Inc. | 5 | $102 |
| Pharming Healthcare, Inc. | 1 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $58 |
| Lundbeck LLC | 2 | $55 |
| Merck | 3 | $45 |
| ANI Pharmaceuticals, Inc. | 2 | $38 |
| Aerin Medical Inc. | 1 | $35 |
| Bayer | 1 | $21 |
| AbbVie | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Vapotherm Inc | 1 | $17 |
| Circassia Inc. | 1 | $15 |
| Novartis | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,052 in reported general payments places this provider in the 80th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 185 | $146,841 |
| Dupixent PenDupilumab | 28 | $129,006 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 109 | $102,783 |
| Ambrisentan | 21 | $98,120 |
| Spiriva RespimatTiotropium Bromide | 60 | $38,030 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 59 | $31,907 |
| SymbicortBudesonide/Formoterol Fumarate | 45 | $17,221 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $12,823 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 55 | $11,414 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 246 | $7,700 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $6,866 |
| EliquisApixaban | 11 | $6,211 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $1,838 |
| Famotidine | 164 | $1,569 |
| Pantoprazole Sodium | 96 | $1,332 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Symbicort | $560 | $164,062230 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $216 | $122,473145 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $179 | $69,937119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Hendersonville
- Robert CookHendersonville$169K
- Selwyn SpangenthalCharlotte$7M
- Thomas SternHuntersville$5.2M
- Laurie SnyderDurham$3.8M
- Scott PalmerDurham$3.8M
- Michael PritchettPinehurst$2.2M
- Anup BanerjeeGastonia$2.1M
- Hubert FordChapel Hill$2M
- Murali RamaswamyGreensboro$2M
- Mikell JarrattGastonia$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.